AnaptysBio is developing a portfolio of novel checkpoint receptor agonist antibodies designed for the treatment of human autoimmune diseases.
Checkpoint receptors are natural inhibitors of immune cells that function to dampen human inflammatory responses. Human checkpoints comprise a family of receptors that includes CTLA-4, PD-1, LAG-3, BTLA and TIGIT.
AnaptysBio believes that immune checkpoint receptors are insufficiently activated in some human inflammatory conditions, and therapeutic modulation with antibodies that augment checkpoint receptor activity has the potential to treat human autoimmune disease. Since checkpoint receptors are expressed by immune cells primarily upon activation, AnaptysBio anticipates that checkpoint receptor agonist antibodies will preferentially suppress disease-causing, auto-reactive immune cells and are therefore less likely to cause broad immunosuppression in patients.
Recent studies conducted by AnaptysBio using its therapeutic candidates have demonstrated that checkpoint receptor agonist antibodies are efficacious in a rodent model of graft-versus-host disease.
Through translational biology, we plan to focus the clinical development of our therapeutic candidates upon certain human autoimmune diseases where checkpoint receptor function is under-represented.
We anticipate that, subsequent to regulatory clearance, one of our wholly-owned checkpoint receptor antibodies will initiate human testing during 2019.